PALVELLA Other Thursday, November 19, 2026 +0.20 Positive

Palvella Files Corporate Presentation For QTORIN Docetaxel Program

Palvella Therapeutics, Inc. filed an 8-K introducing its corporate overview regarding QTORIN Docetaxel, intended for rare skin diseases.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed